Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 5/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3485621 | 0.82 | AVPR1A (0.44) | ALDH1A1KMT2AMEN1MAPTSMN1; SMN2 | |
| SCHEMBL2700969 | 0.80 | CYP2D6 (0.58) | CYP2C9CYP2C19TSHRALDH1A1KMT2A | |
| SCHEMBL2467413 | 0.79 | ALDH1A1 (0.45) | AKR1C3CYP2C9CYP2C19TSHRALDH1A1 | |
| SCHEMBL2702369 | 0.78 | L3MBTL1 (0.54) | TSHRALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL2702729 | 0.78 | CHRM2 (0.59) | CYP2C19TSHRALDH1A1KMT2AMEN1 | |
| SCHEMBL8707282 | 0.77 | CYP2D6 (0.50) | AKR1C3TSHRALDH1A1FKBP1AKMT2A | |
| SCHEMBL923461 | 0.77 | MAOA (0.48) | ALDH1A1HTT | |
| SCHEMBL2702754 | 0.76 | NPC1 (0.63) | TSHRALDH1A1FKBP1AKMT2AMEN1 | |
| SCHEMBL8710585 | 0.76 | SMYD3 (0.54) | CYP2C9CYP2C19TSHRALDH1A1FKBP1A | |
| SCHEMBL2700943 | 0.75 | KDM4E (0.48) | ALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2228065-B1 | Heterocyclo inhibitors of potassium channel function | BRISTOL MYERS SQUIBB CO (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-1501467-B1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2012-05-09 | — | — | EP | disclosed |
| EP-2228065-A2 | Heterocyclo inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2010-09-15 | — | — | EP | disclosed |
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-17 | — | — | US | disclosed |
| US-7582654-B2 | Heterocyclo inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| US-7005436-B2 | Heterocyclo inhibitors of potassium channel function | BRISTOL MYERS SQUIBB COMPANY (US) | 2006-02-28 | — | — | US | disclosed |
| US-20060014792-A1 | Heterocyclo inhibitors of potassium channel function | LLOYD JOHN | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014792-A1 | Heterocyclo inhibitors of potassium channel function | KCNJ2, KCNH2, KCNQ5 | AKR1C3 1469/4885CYP2C9 2232/4885CYP2C19 3045/4885 |
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNJ2, KCNH2, KCNQ5 | AKR1C3 1469/4885CYP2C9 2232/4885CYP2C19 3045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.